tazarotene (tazorac) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Tazarotene is a prodrug and a member of the acetylenic class of retinoids. Following topical application, tazarotene undergoes esterase hydrolysis to form its active metabolite, tazarotenic acid. When treating acne tazarotene may be taken in conjunction with an oral antibiotic. Tazarotene has been shown in peer-reviewed double blinded studies to reduce: mottling and hyperpigmentation, sallowness, fine wrinkling and coarse wrinkling in sun damaged skin. Histological studies have shown that long term (greater than 1 year) use of Tazarotene is associated with a significant reduction in atypical melanocytes and keratocytes - cells considered to be precursors of skin cancer. Some studies have shown long term use of Tazarotene to be associated with increased collagen production and better organization of skin collagen bundles. Although the exact mechanism of tazarotene action is not known, studies have shown that the active form of the drug (tazarotenic acid) binds to all three members of the retinoic acid receptor (RAR) family: RARa, RARb, and RARg, but shows relative selectivity for RARb, and RARg and may modify gene expression. It also has affinity for RXR receptors. Tazarotene is used to treat psoriasis, acne and sun damaged skin (photodamage). Tazarotene is marketed as Tazorac, Avage, Zorac, and Fabior.   NCATS

Chemistry

  • SMILES: CCOC(=O)C1=CN=C(C=C1)C#CC2=CC=C3SCCC(C)(C)C3=C2
  • InChIKey: OGQICQVSFDPSEI-UHFFFAOYSA-N
  • Mol. Mass: 351.462
  • ALogP: 4.43
  • ChEMBL Molecule:
    tazarotene  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$1.8158 - $14.5953
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

3-pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2h-1-benzothiopyran-6-yl)ethynyl)-, ethyl ester | agn 190168 | agn-190168 | avage | ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate | fabior | idp-123 | tazaroc | tazarotene | tazaroteno | tazarotenum | tazorac | zorac

Organizations (57)

Research & Development (47)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (16)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (18)

Approved Indications (5)


 

Acne Vulgaris (approved 2000)

Hypopigmentation

Lentigo

Onychomycosis

Psoriasis (approved 2000)

Experimental Indications - Clinical Trial Phases 1-4 (15)


 

Acne Keloid (Phase 3)

Acne Vulgaris (Phase 4)

Coronary Artery Disease (Phase 4)

Dermatology (Phase 2)

Erythema (Phase 4)

Exanthema (Phase 2)

Inflammation (Phase 4)

Lymphoma, T-Cell, Cutaneous (Phase 1/Phase 2)

Nails (Phase 4)

Neoplasms (Phase 2)

Neoplastic Syndromes, Hereditary (Phase 2)

Psoriasis (Phase 4)

Skin Diseases (Phase 4)

Skin Neoplasms (Phase 2)

Warts (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 60
  • # of Trial Organizations: 47

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue